Generic Tadalafil 20mg — How the Market Opened After Patent Expiry in 2018

Home › Cialis (Tadalafil) › Generic 20mg

Generic Overview

Generic Tadalafil 20mg — FDA Approval Process and What Differs From Brand Cialis

When a prescription drug's patent expires, other manufacturers may apply to sell a chemically equivalent product under the generic approval pathway. This is not a shortcut — it is a distinct regulatory process with its own requirements. For tadalafil 20mg, that process began with Eli Lilly's US compound patent expiring on September 27, 2018. Understanding what generic approval means, and what it does not change, clarifies a question many patients have about the drugs their pharmacist may now dispense.

Tadalafil's Path From Patent Protection to Generic Competition

Tadalafil was originally developed by ICOS Corporation, a biotechnology company founded in Bothell, Washington in 1990. ICOS partnered with Eli Lilly and Company to develop and commercialize the drug, and Lilly ultimately acquired ICOS in 2007. The FDA approved Cialis on November 21, 2003.

The key US intellectual property protection was US Patent 5,859,006, which covered the tadalafil compound itself. This patent's expiration on September 27, 2018 was the event that determined when generic manufacturers could legally enter the market. Secondary patents on specific formulations and methods of use had additional expiry timelines, but the compound patent was the primary barrier for most generic ANDA filers.

Eli Lilly reached a settlement agreement in 2015 with Actavis (at that time a subsidiary of Allergan, later acquired by AbbVie) that allowed Actavis to market an authorized generic beginning on the compound patent's expiration date. Under this settlement, Lilly authorized Actavis to distribute a version of Cialis at a lower price beginning September 27, 2018 — a common industry arrangement known as an authorized generic launch, which allows the brand manufacturer to participate in the generic market while the brand continues at its original price.

How the FDA Approves a Generic Drug: The ANDA Process

Generic drugs in the United States are approved via the Abbreviated New Drug Application (ANDA) process established under the Hatch-Waxman Act of 1984. The "abbreviated" designation reflects the key point: a generic applicant does not repeat the full clinical efficacy and safety trials that the original manufacturer conducted. Instead, it demonstrates that its product is bioequivalent to the already-approved reference listed drug (RLD) — in this case, tadalafil 20mg (Cialis).

Bioequivalence is established through pharmacokinetic studies — typically two-way crossover trials in healthy volunteers — measuring area under the plasma concentration-time curve (AUC) and peak plasma concentration (Cₚₘₓ). The FDA requires that the 90% confidence interval for the geometric mean ratio of each parameter fall within 80% to 125% of the reference product. This range is expressed as a ratio, not an absolute difference. A generic whose average AUC is exactly equal to the brand's would show a ratio of 1.0, well within the acceptable window; a generic showing an average AUC 15% lower would still be within bounds.

This standard has been in place since the 1990s and applies to hundreds of thousands of approved generic ANDAs. The 80–125% window was selected based on pharmacological modeling of what degree of pharmacokinetic variation is unlikely to produce a clinically detectable difference in effect for most patients.

What Changes and What Stays the Same in a Generic Tablet

When a patient switches from brand-name Cialis to generic tadalafil, the following elements are legally required to remain identical:

  • Active ingredient: tadalafil
  • Strength: 20mg per tablet
  • Route of administration: oral
  • Dosage form: tablet
  • Labeling: therapeutically equivalent (same core clinical information)

The following elements may legally differ between brand and generic:

  • Inactive ingredients (excipients): binders, fillers, coatings, colorants, and disintegrants can be different. Brand Cialis 20mg tablets use excipients including lactose monohydrate, croscarmellose sodium, hydroxypropyl cellulose, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, hypromellose, titanium dioxide, talc, and a yellow iron oxide-based film coat. Generic tablets vary by manufacturer and do not use the same excipient set.
  • Appearance: Brand Cialis 20mg is a yellow, almond-shaped, film-coated tablet imprinted with "C 20." Generic tablets from different manufacturers are different shapes, colors, and imprints — a white or pale yellow round tablet is common, though specifics differ by manufacturer.
  • Packaging: Brand Cialis uses distinctive blister packaging; generic packaging varies.

Pharmacy Substitution and How It Works

In most US states, pharmacists are permitted — and in some states required — to substitute an FDA-approved generic equivalent for a brand-name drug unless the prescriber writes "dispense as written" (DAW) on the prescription. This is called generic substitution or therapeutic substitution. When a physician prescribes "tadalafil 20mg" without brand specification, the pharmacist will typically dispense whichever FDA-approved generic manufacturer they stock. When a physician specifies "Cialis," the pharmacist may still substitute a generic unless DAW is indicated.

Patients who notice a difference after switching to a new generic from a different manufacturer should speak with their pharmacist. While statistically the pharmacokinetic profile must be within the bioequivalence window, individual patients with variable absorption may in practice respond somewhat differently to formulations. This is more of a theoretical concern than a well-documented clinical problem for tadalafil specifically, given its long half-life and forgiving pharmacokinetics.

Regulatory Context

The FDA Orange Book and Generic Equivalence Ratings

The FDA maintains the Orange Book (formally titled "Approved Drug Products with Therapeutic Equivalence Evaluations"), a publicly accessible database listing every FDA-approved drug and its approved generic equivalents. Each generic is assigned a therapeutic equivalence (TE) code indicating whether it has been found therapeutically equivalent to the reference listed drug.

An "AB" rating — the most common code in the Orange Book — indicates that a generic has been found therapeutically equivalent to the brand based on bioequivalence data, meaning it may legally be substituted for the brand in states that permit substitution. Generic tadalafil products approved under the tadalafil ANDA pathway carry AB ratings, as the bioequivalence studies compared directly to Cialis as the reference product. Patients or healthcare providers can look up specific manufacturers' approvals in the Orange Book using tadalafil as the generic name.

Manufacturing Quality and Regulatory Oversight

A common concern among patients switching to generics is whether manufacturers cut corners on quality to lower costs. The FDA addresses this through Current Good Manufacturing Practice (cGMP) regulations, which apply equally to brand-name and generic drug manufacturers. cGMP requirements cover facility design, equipment calibration, raw material testing, in-process quality checks, finished product testing, and documentation standards.

The FDA inspects generic manufacturing sites both in the United States and internationally, issuing Warning Letters and Import Alerts when cGMP deficiencies are found. A Warning Letter is a matter of public record and available on the FDA website. The agency's inspection history for facilities producing tadalafil generics provides one basis for evaluating manufacturer quality compliance, though individual product quality is also assessed by the facility's own quality control testing with each production batch.

About This Page

This article is informational only and does not constitute medical advice. Patent expiry dates and bioequivalence standards are drawn from FDA Orange Book records, the Hatch-Waxman Act framework, and FDA guidance on bioequivalence for oral immediate-release solid dosage forms. The 80–125% bioequivalence standard is cited from FDA's guidance document "Statistical Approaches to Establishing Bioequivalence." Reviewed by a medical writing team, April 2026.